AP News, November 10, 2025: AP explains FDA decision to
delete most black box warnings for hormone therapy for menopause,
despite controversies about the risks. NCHR’s Diana Zuckerman
says FDA lost credibility for deleting such important warnings without
scientific review using FDA Advisory Committee.
Medical Care for Adults
The National Center for Health Research reviews important new research as soon as it is published. We cut through the hype regarding various medical treatments to let you know what is proven and what is unknown about the risks and benefits of various treatment options. We do not accept funding from the companies that make medical products, so you can trust that our information is based on science, and not biased by financial ties to the treatments we’re evaluating.
To find the information you need, please use our search box to search for exactly what you are looking for or browse through our various topics on the right. →
Some of these articles were written this year and others were not, however, if they are on our website it means the information is up-to-date. We always scrutinize new research and call the researchers to learn even more. Then we translate it into plain language that everyone can understand.
If you’re looking for more detailed information about cancer, please go to our Cancer Prevention and Treatment website.
If you don’t see what you are looking for on any health topic, please contact us and we will try to get the information you need within a few days.
Some MAHA Supporters Say CNPV Could Lower FDA Standards
October 23, 2025: Inside Health Policy quotes a MAHA meeting that criticized industry influence over FDA, the impact of user fees, the inappropriate reliance on surrogate endpoints for cancer screening and Alzheimer’s drugs. The Lever FDA report finding that most new drugs are approved on evidence inferior to the FDA’s legal standards. NCHR’s Diana Zuckerman is quoted criticizing the FDA’s new CNVP program that promises extremely fast priority reviews for high-impact drugs.
Read More »Heart Disease in Women
Heart disease is the leading cause of death for U.S. women and men, but it often has different causes, symptoms, and risks for women, especially after menopause. Biological differences and the underrepresentation of women patients in cardiovascular research result in less effective prevention and treatment for women. Learn more about how early screening, exercise, and healthy habits can prevent disease, and the research needed to learn more about treating women with heart disease.
Read More »NCHR Comments on Coverage of Colorectal Cancer Non-Invasive Biomarker Screening Tests
NCHR public comment tells CMS that the ColoSense multi-target mRNA stool-based colorectal cancer screening test needs better evidence to qualify for Medicare NCD coverage. The study sample included 3x the average number of smokers in the U.S. and since smoking increases the chances of colon cancer, that may have biased the results to make the test seem more accurate than it really is. Too many false positives or false negatives would make the test much less useful for patients.
Read More »Breakthrough Devices
NCHR analysis of FDA breakthrough devices, their approval pathways, and the evidence available for safety and effectiveness.
Read More »